Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list.

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

The on-and-off availability of compounded tirzepatide and semaglutide drugs has also impacted the stock market, triggering significant fluctuations in shares for Hims & Hers in particular.

A trial exploring the use of a higher dose ... Act. Tirzepatide will be protected from inclusion in the negotiation list until 2030, as it was first approved in 2022, while semaglutide has been ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Prices would require additional discounts of 30.5% and 81.9% for tirzepatide and semaglutide, respectively, from the current net prices to be cost-effective. HealthDay News — Tirzepatide and ...